Related Experiment Videos

A c-ras-Ki oncogene is activated, amplified and overexpressed in a human osteosarcoma cell line

Insights

Researchers identified an activated oncogene, c-ras-Ki 2, in osteosarcoma cells. This gene, mutated and amplified, leads to an abnormal p21 protein, driving tumor cell transformation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Osteosarcoma is a malignant bone tumor.
  • Proto-oncogenes can become activated oncogenes, driving cancer development.
  • The Kirsten ras (Ki-ras) family are known proto-oncogenes implicated in various cancers.

Purpose of the Study:

  • To characterize an activated oncogene found in the OHA osteosarcoma cell line.
  • To identify the specific gene and its mutations responsible for tumor cell transformation.
  • To investigate the expression and protein product of the identified oncogene.

Main Methods:

  • DNA sequencing to identify point mutations.
  • Gene amplification analysis.
  • Western blot or similar techniques to analyze protein expression and function.

Main Results:

  • The activated oncogene was identified as c-ras-Ki 2, a member of the Kirsten ras family.
  • A single point mutation (Glycine to Valine at codon 12) was detected in the c-ras-Ki 2 gene.
  • The c-ras-Ki 2 gene was found to be amplified and overexpressed in OHA cells and their transformants.
  • An abnormal p21 protein product was observed, resulting from the mutated and overexpressed gene.

Conclusions:

  • The identified c-ras-Ki 2 gene is an activated oncogene driving osteosarcoma.
  • The specific point mutation and gene amplification contribute to the oncogenic phenotype.
  • The abnormal p21 protein is likely responsible for the transformation of cells.

Related Concept Videos